Conclusions
Eribulin has effects on the tumor cell and microenvironment that
differ
from other microtubule targeting agents
Eribulin
improves survival
in patients with advanced breast cancer
previously treated with a taxane and an anthracycline
Certain subgroups may receive an additional OS benefit from eribulin:
– patients with
HER2-negative or triple-negative disease
Future research is needed to optimize the role of eribulin in the
treatment of MBC, in terms of optimal
patient selection
and its best place
in the therapeutic arsenal.
